An ad hoc group formed by NCI to provide advice on the slowly-accruing TMIST—Tomosynthesis Mammographic Imaging Screening Trial—recommended that the trial be streamlined, but should continue.
NCI has established a program at Frederick National Laboratory to manufacture CAR T-cell therapies for multicenter clinical trials.
Hackensack Meridian Health and the Genomic Testing Cooperative are establishing a genomic profiling laboratory called Anthology Diagnostics, to generate more personalized, precise, and real-time insights for cancer patients, oncologists and hospitals.
Stand Up To Cancer, Exact Sciences, and Academy Award winner Jamie Foxx are collaborating on a public service announcement to raise awareness about colorectal cancer screenings, early detection and prevention.
McKesson has launched ScriptPAS, a pharmacy management solution for oncology practices powered by Biologics by McKesson specialty pharmacy.
Eight nonprofits have received a total of $450,000 from Novartis through the company’s STEP Program.
Even with access to a clinical trial, cancer patients living in the poorest neighborhoods in America have a nearly 30% greater chance of dying from their disease compared to the wealthiest patients, SWOG Cancer Research Network study results show.
ILLUMINATE-301, the registration trial of tilsotolimod in combination with Yervoy (ipilimumab) versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate.
Aveo Oncology and Bristol Myers Squibb are collaborating on a phase III clinical trial to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab) in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
Researchers at Johns Hopkins Kimmel Cancer Center developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
